Adalimumab in the Treatment of Immune-Mediated Diseases

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue , 2014, Pages 33-48

  Lapadula, G ^a   Marchesoni, A ^b   Armuzzi, A ^c   Blandizzi, C ^d   Caporali, R ^e   Chimenti, S ^f   Cimaz, R ^g   Cimino, L ^h,j   Gionchetti, P ^k   Girolomoni, G ⁱ   Lionetti, P ^g   Marcellusi, A ^f   Mennini, F S ^f   Salvarani, C ^h  

^a UNIVERSITY OF BARI   (Italy)

^b G Pini Orthopaedic Institute   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g UNIVERSITY OF FLORENCE   (Italy)

^h S MARIA NUOVA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k University of Tor Vergata ^*

more..

Author keywords

Adalimumab; anti TNF therapy; immune mediated disorders; tumour necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; INFLIXIMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT DISEASE; ANKYLOSING SPONDYLITIS; BEHCET DISEASE; CHILDHOOD DISEASE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOGENICITY; IMMUNOPATHOLOGY; INFECTION RISK; INFLAMMATORY DISEASE; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION; ULCERATIVE COLITIS; ANIMAL; AUTOIMMUNE DISEASE; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; ECONOMICS; IMMUNOLOGY; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; INFLAMMATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900819562     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/03946320140270S103     Document Type: Review

References (88)

1. Kuek A., Hazleman B.L., Ostor A.J., Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Postgrad Med J 2007; 83: 251-60.
2. Zhernakova A., van Diemen C.C., Wijmenga C., Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009; 10: 43-55.
3. Lees C.W., Barrett J.C., Parkes M., Satsangi J., New IBD genetics: Common pathways with other diseases. Gut 2011; 60: 1739-53.
4. Cohen A.D., Dreiher J., Birkenfeld S., Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23: 561-5.
5. Najarian D.J., Gottlieb A.B., Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 2003; 48: 805-21; quiz 22-4.
6. Li W.Q., Han J.L., Chan A.T., Qureshi A.A., Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis 2012.
7. Mosquera-Martinez J.A., Rheumatoid arthritis associated with ulcerative colitis. Ann Rheum Dis 2001; 60: 1155.
8. Boyer F., Fontanges E., Miossec P., Rheumatoid arthritis associated with ulcerative colitis: A case with severe flare of both diseases after delivery. Ann Rheum Dis 2001; 60: 901.
9. Cruz V.A., Yamaguchi L., Ribeiro C.N., Vde O. Magalhaes, Rego J., Silva N.A., Ulcerative colitis and rheumatoid arthritis: A rare association-case report. Rev Bras Reumatol 2012; 52: 648-50.
10. Aydin Y., Ozcakar L., Yildiz M., Akinci A., Liaison between rheumatoid arthritis and ulcerative colitis. Rheumatol Int 2003; 23: 47-8.
11. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al.The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
12. Lovell D.J., Ruperto N., Goodman S., et al.Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. The New England journal of medicine 2008; 359: 810-20.
13. Nash P.T., Florin T.H., Tumour necrosis factor inhibitors. Med J Aust 2005; 183: 205-8.
14. Silva L.C., Ortigosa L.C., Benard G., Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: Mechanisms of action and pitfalls. Immunotherapy 2010; 2: 817-33.
15. Firestein G.S., Corr M., Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl 2005; 73: 8-13; discussion 29-30.
16. Furst D.E., Keystone E.C., Braun J., et al.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 Suppl 2: i2-45.
17. Taylor P.C., Williams R.O., Feldmann M., Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 2004; 15: 557-63.
18. Savarino E., Bodini G., Dulbecco P., et al.Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial. Am J Gastroenterol 2013.
19. West C., Narahari S., O'Neill J., et al.Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J 2013; 19: 18182.
20. Taylor P.C., Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010; 10: 308-15.
21. Thalayasingam N., Isaacs J.D., Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011; 25: 549-67.
22. Murdaca G., Colombo B.M., Puppo F., Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Bare) 2011; 47: 277-88.
23. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al.Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
24. Weinblatt M.E., Keystone E.C., Furst D.E., et al.Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
25. van der Heijde D., Schiff M. H., Sieper J., et al.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: Long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922-9.
26. Rudwaleit M., Van den Bosch F., Kron M., Kary S., Kupper H., Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12: R117.
27. Sieper J., van der Heijde D., Dougados M., et al.Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013; 72: 815-22.
28. Gladman D.D., Mease P.J., Ritchlin C.T., et al.Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56: 476-88.
29. Gordon K.B., Langley R.G., Leonardi C., et al.Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
30. Saurat J.H., Stingl G., Dubertret L., et al.Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
31. Colombel J.F., Sandborn W.J., Rutgeerts P., et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007; 132: 52-65.
32. Schreiber S., Reinisch W., Colombel J.F., et al.Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013; 7: 213-21.
33. Sandborn W.J., van Assche G., Reinisch W., et al.Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65 e1-3.
34. Sandborn W.J., Colombel J.F., D'Haens G., et al.One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
35. Burmester G.R., Mease P., Dijkmans B.A., et al.Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9.
36. Burmester G.R., Panaccione R., Gordon K.B., McIlraith M.J., Lacerda A.P., Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012.
37. Burmester G.R., Panaccione R., Gordon K.B., McIlraith M.J., Lacerda A.P., Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72: 517-24.
38. Garces S., Demengeot J., Benito-Garcia E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis. Ann Rheum Dis 2012.
39. Spinelli F.R., Valesini G., Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol 2013.
40. Jani M., Barton A., Warren R.B., Griffiths C.E., Chinoy H., The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2013.
41. Jullien D., [Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis]. Ann Dermatol Venereol 2012; 139 Suppl 2: S58-67.
42. Andrisani G., Gremese E., Guidi L., et al.Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis. In press 2013.
43. Garces S., Antunes M., Benito-Garcia E., da Silva J.C., Aarden L., Demengeot J., A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2013.
44. Vincent F.B., Morand E.F., Murphy K., Mackay F., Mariette X., Marcelli C., Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: A real issue, a clinical perspective. Ann Rheum Dis 2013; 72: 165-78.
45. Ordas I., Mould D.R., Feagan B.G., Sandborn W.J., Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. Clinical pharmacology and therapeutics 2012; 91: 635-46.
46. Lofberg R., Louis E.V., Reinisch W., Robinson A.M., Kron M., Camez A., Pollack P.F., Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE. Inflamm Bowel Dis 2012; 18: 1-9.
47. Rudwaleit M., Rodevand E., Holck P., Vanhoof J., Kron M., Kary S., Kupper H., Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Ann Rheum Dis 2009; 68: 696-701.
48. Rebelo A., Leite S., Cotter J., Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab. BioDrugs 2010; 24 Suppl 1: 37-9.
49. Weng X., Liu L., Barcellos L.F., Allison J.E., Herrinton L.J., Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. Am J Gastroenterol 2007; 102: 1429-35.
50. Kappelman M.D., Galanko J.A., Porter C.Q., Sandler R.S., Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child 2011; 96: 1042-6.
51. Palm O., Mourn B., Jahnsen J., Gran J.T., The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology (Oxford) 2001; 40: 1256-61.
52. Braun J., Rudwaleit M., Kary S., Kron M., Wong R.L., Kupper H., Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. Rheumatology (Oxford) 2010; 49: 1578-89.
53. Rudwaleit M., Claudepierre P., Kron M., Kary S., Wong R., Kupper H., Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther 2010; 12: R43.
54. Zannin M.E., Birolo C., Gerloni V.M., et al.Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 2013; 40: 74-9.
55. Kotaniemi K., Saila H., Kautiainen H., Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011; 5: 1425-9.
56. Moretti D., Cianchi I., Vannucci G., Cimaz R., Simonini G., Psoriatic juvenile idiopathic arthritis associated with uveitis: A case report. Case Rep Rheumatol 2013; 2013: 595890.
57. Yildiz N., Alkan H., Ardic F., Topuz O., Successful treatment with adalimumab in a patient with coexisting Behcet's disease and ankylosing spondylitis. Rheumatol Int 2010; 30: 1511-4.
58. van der Heijde D., Kivitz A., Schiff M. H., et al.Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
59. Hyams J.S., Griffiths A., Markowitz J., et al.Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012; 143: 365-74 e2.
60. Tynjala P., Kotaniemi K., Lindahl P., Latva K., Aalto K., Honkanen V., Lahdenne P., Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008; 47: 339-44.
61. Yokota S., Imagawa T., Murata T., et al.Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan. Modern rheumatology / the Japan Rheumatism Association 2012; 22: 491-7.
62. Shenoi S., Wallace C.A., Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: An evidence-based review. Paediatr Drugs 2010; 12: 367-77.
63. Sacks J.J., Helmick C.G., Luo Y.H., Ilowite N.T., Bowyer S., Prevalence of and annual ambulatory health care visits for pediatric arthritis and other rheumatologic conditions in the United States in 2001-2004. Arthritis Rheum 2007; 57: 1439-45.
64. Katsicas M.M., Russo R.A., Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 2009; 28: 985-8.
65. Imagawa T., Takei S., Umebayashi H., et al.Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 2012; 31: 1713-21.
66. Heyman M.B., Kirschner B.S., Gold B.D., et al.Children with early-onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD consortium registry. J Pediatr 2005; 146: 35-40.
67. Motil K.J., Grand R.J., Davis-Kraft L., Ferlic L.L., Smith E.O., Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology 1993; 105: 681-91.
68. Kugathasan S., Judd R.H., Hoffmann R.G., et al.Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A statewide population-based study. J Pediatr 2003; 143: 525-31.
69. Assa A., Hartman C., Weiss B., et al.Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis 2012.
70. Pallotta N., Civitelli F., Di Nardo G., et al.Small intestine contrast ultrasonography in pediatric Crohn's disease. J Pediatr 2013; 163: 778-84 e1.
71. Markowitz J., Current treatment of inflammatory bowel disease in children. Dig Liver Dis 2008; 40: 16-21.
72. Martin-De-Carpi J., Pociello N., Varea V., Long-term efficacy of adalimumab in paediatric Crohn's disease patients naive to other anti-TNF therapies. J Crohns Colitis 2010; 4: 594-8.
73. Rosh J.R., Lerer T., Markowitz J., et al.Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009; 104: 3042-9.
74. Viola F., Civitelli F., Di Nardo G., et al.Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009; 104: 2566-71.
75. Rosenbach Y., Hartman C., Shapiro R., Hirsch A., Avitzur Y., Shamir R., Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci 2010; 55: 747-53.
76. Malik S., Ahmed S.F., Wilson M.L., et al.The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn's disease (CD). J Crohns Colitis 2012; 6: 337-44.
77. Malottki K., Barton P., Tsourapas A., et al.Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-278.
78. Doan Q.V., Chiou C.F., Dubois R.W., Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006; 12: 555-69.
79. Binion D.G., Louis E., Oldenburg B., Mulani P., Bensimon A.G., Yang M., Chao J., Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: A meta-analysis. Can J Gastroenterol 2011; 25: 492-6.
80. Louis E., Lofberg R., Reinisch W., et al.Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial. J Crohns Colitis 2013; 7: 34-43.
81. Mennini F.S., Marcellusi A., Gitto L., Giannantoni P., Favato G., Comprehensive value estimation of adalimumab-based treatments: Covet study [PHP36]. Value Health 2012; 15: A19.
82. Marcellusi A., Gitto L., Giannantoni P., Russo S., Mennini F.S., Social impact of adalimumab in the Italian perspective [PIH26]. Value Health 2012; 15: A540.
83. Smolen J.S., Landewe R., Breedveld F.C., et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
84. European League Against Rheumatism (EULAR). EULAR issues updated rheumatoid arthritis (RA) management recommendations. 2013 [cited 2013 October 11]; Available from: http://www.eular.org/myUploadData/files/EULAR%20RA%20recommendations%20FINAL.pdf
85. Smolen J.S., Landewe R., Breedveld F.C., et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013.
86. Caporali R., Conti F., Alivernini S., et al.Recommendations for the use of biologic therapy in rheumatoid arthritis: Update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 2011; 29: S7-14.
87. Singh J.A., Furst D.E., Bharat A., et al.2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
88. Bansback N., Brennan A., Anis A.H., A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res 2005; 5: 519-29.